Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1977 2
1978 2
1979 1
1982 1
1983 2
1985 1
1986 1
1987 1
1988 1
1990 3
1991 1
1993 3
1994 4
1995 3
1996 1
1997 2
1999 2
2000 1
2001 2
2002 2
2003 3
2004 4
2005 1
2006 2
2007 2
2008 4
2009 3
2010 1
2011 4
2012 3
2013 4
2014 5
2015 7
2016 5
2017 1
2018 2
2019 7
2020 7
2021 8
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Non-Neoplastic Hematologic and Lymphocytic Disorder"
Page 1
Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach.
Hue SS, Oon ML, Wang S, Tan SY, Ng SB. Hue SS, et al. Pathology. 2020 Jan;52(1):111-127. doi: 10.1016/j.pathol.2019.09.011. Epub 2019 Nov 22. Pathology. 2020. PMID: 31767131 Review.
Epstein-Barr virus (EBV)-positive T-cell and natural killer (NK)-cell lymphoproliferative diseases (EBV-TNKLPD) are a group of uncommon disorders characterised by EBV infection of T- and NK-cells. As a group, EBV-TNKLPD are more commonly encountered in Asians and Native Am …
Epstein-Barr virus (EBV)-positive T-cell and natural killer (NK)-cell lymphoproliferative diseases (EBV-TNKLPD) are a group of uncomm …
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A. Sallman DA, et al. Lancet Haematol. 2023 Mar;10(3):e191-e202. doi: 10.1016/S2352-3026(22)00378-7. Epub 2023 Feb 7. Lancet Haematol. 2023. PMID: 36764323 Clinical Trial.
BACKGROUND: CYAD-01 is an autologous chimeric antigen receptor (CAR) T-cell product based on the natural killer (NK) group 2D (NKG2D) receptor, which binds eight ligands that are overexpressed in a wide range of haematological malignancies but are largely absent on non- …
BACKGROUND: CYAD-01 is an autologous chimeric antigen receptor (CAR) T-cell product based on the natural killer (NK) group 2D (NKG2D) recept …
The Importance of Nephropathology in Kidney Cancer.
Henriksen KJ, Chang A. Henriksen KJ, et al. Semin Nephrol. 2020 Jan;40(1):69-75. doi: 10.1016/j.semnephrol.2019.12.008. Semin Nephrol. 2020. PMID: 32130968 Review.
Given that diabetes, hypertension, obesity, cigarette smoking, and aging are independent risk factors for renal cell carcinoma, the corresponding non-neoplastic kidney diseases frequently are present, but often undiagnosed. ...Awareness of these practice gaps …
Given that diabetes, hypertension, obesity, cigarette smoking, and aging are independent risk factors for renal cell carcinoma, the correspo …
Health status of petrochemical workers: a narrative review.
Fassio F, Bussa M, Oddone E, Ferraro OE, Puci MV, Morandi A, Castaldo F, Broi M, Uberti F, Villani S, Montomoli C, Monti MC. Fassio F, et al. G Ital Med Lav Ergon. 2022 Mar;44(1):51-58. G Ital Med Lav Ergon. 2022. PMID: 36346299 Review. English.
We used the PubMed and Web of Science search engines. As regards non-neoplastic diseases, despite heterogeneous prevalence estimates, we could say that standardized mortality rate (SMR) for hypertension, hypercholesterolemia and diabetes does not increase ove …
We used the PubMed and Web of Science search engines. As regards non-neoplastic diseases, despite heterogeneous prevale …
Marrow outside marrow: imaging of extramedullary haematopoiesis.
Malla S, Razik A, Das CJ, Naranje P, Kandasamy D, Kumar R. Malla S, et al. Clin Radiol. 2020 Aug;75(8):565-578. doi: 10.1016/j.crad.2019.12.016. Epub 2020 Jan 20. Clin Radiol. 2020. PMID: 31973940 Review.
Extramedullary haematopoiesis (EMH) refers to the formation of non-neoplastic blood cell lines outside the bone marrow and is a common incidental finding when patients with haematological disorders are imaged. ...
Extramedullary haematopoiesis (EMH) refers to the formation of non-neoplastic blood cell lines outside the bone marrow and is …
Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review.
Hsieh CY, Tsai TF. Hsieh CY, et al. Clin Drug Investig. 2020 Oct;40(10):915-926. doi: 10.1007/s40261-020-00956-w. Clin Drug Investig. 2020. PMID: 32691244 Review.
A literature search was performed on Pubmed and Embase, targeting articles indicating neutropenia as a complication during the treatment of non-neoplastic dermatological disorders. In 66 identified articles, the common incriminated drugs included conventional oral i …
A literature search was performed on Pubmed and Embase, targeting articles indicating neutropenia as a complication during the treatment of …
Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients.
Chistolini A, Serrao A, Assanto GM, Genoese A, Baldacci E, Ligia S, Breccia M, Santoro C. Chistolini A, et al. Ann Hematol. 2023 Sep;102(9):2599-2605. doi: 10.1007/s00277-023-05369-1. Epub 2023 Jul 21. Ann Hematol. 2023. PMID: 37479891
We included 154 patients: 53 patients affected by hematological malignancies compared to 101 non-neoplastic patients. During full-dose treatment, no thrombotic recurrences were observed in the two groups. ...During low-dose therapy, 4/154 (2.6%) bAE were observed: 3 …
We included 154 patients: 53 patients affected by hematological malignancies compared to 101 non-neoplastic patients. During f …
B lymphocytes transdifferentiate into immunosuppressive erythroblast-like cells.
Yang Z, Wang Z, Wu L, Wang Y, Xu Z, Liu Y, Wang F, Yu D. Yang Z, et al. Front Immunol. 2023 Jul 21;14:1202943. doi: 10.3389/fimmu.2023.1202943. eCollection 2023. Front Immunol. 2023. PMID: 37545522 Free PMC article.
Under conditions of hypoxia, mouse B lymphoma cells are capable of converting to erythroblast-like cells, which display phenotypes of CD45(+)TER119(+) cells, including immunosuppressive effects on CD8 T cells. Furthermore, non-neoplastic B cells have similar differe …
Under conditions of hypoxia, mouse B lymphoma cells are capable of converting to erythroblast-like cells, which display phenotypes of CD45(+ …
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
Spivak JL, Hasselbalch H. Spivak JL, et al. Expert Rev Anticancer Ther. 2011 Mar;11(3):403-14. doi: 10.1586/era.11.10. Expert Rev Anticancer Ther. 2011. PMID: 21417854 Review.
Hydroxycarbamide is a nonalkylating antiproliferative and antiviral agent that has been used for over 40 years to treat a variety of neoplastic and non-neoplastic conditions. Hydroxycarbamide is readily absorbed and widely distributed throughout the body. ...
Hydroxycarbamide is a nonalkylating antiproliferative and antiviral agent that has been used for over 40 years to treat a variety of neoplas …
111 results